QQ客服 官方微博 反馈留言

浏览/检索结果: 共8条，第1-8条 帮助 限定条件 发表日期：2021     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Clinical outcomes of lung adenocarcinoma patients harboring uncommon epidermal growth factor receptor (EGFR) mutations treated with EGFR-tyrosine kinase inhibitors (TKIs) 期刊论文 ANNALS OF PALLIATIVE MEDICINE, 2021 作者:  Si, Jinfei;  Gu, Xiaodong;  Wang, Wenxian;  Ying, Shenpeng;  Song, Zhengbo 收藏  |  浏览/下载：59/0  |  提交时间：2022/02/14 Epidermal growth factor receptor (EGFR)  uncommon mutation  compound mutation  double uncommon mutation  lung adenocarcinoma (lung AC)   LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo 期刊论文 CANCER SCIENCE, 2021, 页码: 12 作者:  Liu, Yingqiang;  Lai, Mengzhen;  Li, Shan;  Wang, Yanan;  Feng, Fang 收藏  |  浏览/下载：62/0  |  提交时间：2022/01/18 C797S  epidermal growth factor receptor  fourth-generation EGFR TKI  non-small cell lung cancer  osimertinib resistance   Effect of autoinduction and food on the pharmacokinetics of furmonertinib and its active metabolite characterized by a population pharmacokinetic model 期刊论文 ACTA PHARMACOLOGICA SINICA, 2021, 页码: 10 作者:  Zou, Hui-xi;  Zhang, Yu-feng;  Zhong, Da-fang;  Jiang, Yong;  Liu, Fei 收藏  |  浏览/下载：19/0  |  提交时间：2022/01/04 furmonertinib  autoinduction  food effect  alkaline phosphatase  body weight  pharmacokinetics  modeling and simulation  NSCLC   The correlation between the abundance of EGFR T790M mutation and osimertinib response in advanced non-small cell lung cancer 期刊论文 TRANSLATIONAL CANCER RESEARCH, 2021, 卷号: 10 作者:  Pan, Guoqiang;  Chen, Kaiyan;  Yu, Xiaoqing;  Sheng, Jiamin;  Fan, Yun 收藏  |  浏览/下载：38/0  |  提交时间：2021/11/01 Non-small cell lung cancer (NSCLC)  T790M abundance  droplet digital PCR (ddPCR)  next generation sequencing (NGS)  osimertinib   Metabolic disposition of the EGFR covalent inhibitor furmonertinib in humans 期刊论文 ACTA PHARMACOLOGICA SINICA, 2021, 页码: 10 作者:  Meng, Jian;  Zhang, Hua;  Bao, Jing-jing;  Chen, Zhen-dong;  Liu, Xiao-yun 收藏  |  浏览/下载：69/0  |  提交时间：2021/06/11 metabolism  mass balance  distribution  covalent binding  furmonertinib   Metabolic disposition of the EGFR covalent inhibitor furmonertinib in humans 期刊论文 ACTA PHARMACOLOGICA SINICA, 2021, 页码: 10 作者:  Meng, Jian;  Zhang, Hua;  Bao, Jing-jing;  Chen, Zhen-dong;  Liu, Xiao-yun 收藏  |  浏览/下载：71/0  |  提交时间：2021/06/11 metabolism  mass balance  distribution  covalent binding  furmonertinib   Third-generation EGFR inhibitor HS-10296 in combination with famitinib, a multi-targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR-mutant non-small cell lung cancer cells 期刊论文 THORACIC CANCER, 2021, 页码: 9 作者:  Zhang, Mi;  Quan, Haitian;  Fu, Li;  Li, Yun;  Fu, Haoyu 收藏  |  浏览/下载：19/0  |  提交时间：2021/05/24 EGFR‐  mutant non‐  small cell lung cancer  famitinib  HS‐  10296  multi‐  targeted tyrosine kinase inhibitor  third‐  generation EGFR inhibitor   Effects of rifampicin on the pharmacokinetics of alflutinib, a selective third-generation EGFR kinase inhibitor, and its metabolite AST5902 in healthy volunteers 期刊论文 INVESTIGATIONAL NEW DRUGS, 2021, 页码: 8 作者:  Zhu, Yun-ting;  Zhang, Yi-fan;  Jiang, Jin-fang;  Yang, Yong;  Guo, Li-xia 收藏  |  浏览/下载：27/0  |  提交时间：2021/05/24 Alflutinib  Rifampicin  CYP3A4  AST5902  Drug-drug interaction